Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The use of calendula for its lenitive properties’ dates to the XII century. This plant contains several bioactive compounds, including terpenoids, terpenes, carotenoids, flavonoids and polyunsaturated fatty acids. Calendula flower extract is used in soothing cosmetics, such as after-sun, sensitive skin and eye contour products. The anti-inflammatory properties of this ingredient were demonstrated in an animal model, but the mechanism of action is poorly understood. Therefore, our work explored the effect of a calendula flower extract on NO production, a pro-inflammatory radical produced by nitric oxide synthase (iNOS) and highly released by innate immune cells in inflammatory-related pathologies. NO production was evoked by the Toll-like receptor 4 agonist lipopolysaccharide (LPS) in macrophages, using concentrations that did not compromise cells viability. This ingredient exhibited a dose-dependent NO inhibition, reaching 50% at 147 μL/mL without cytotoxicity. Together with previous literature, these results provide experimental evidence on the anti-inflammatory properties of calendula flower extract, as well as its usefulness in cosmetics with soothing properties and adjunctive skin care in the treatment of the diseases associated with dysregulation of the NO signaling cascade.

Details

Title
Anti-Inflammatory Activity of Calendula officinalis L. Flower Extract
Author
Silva, Diva 1 ; Marta Salvador Ferreira 2   VIAFID ORCID Logo  ; Sousa-Lobo, José Manuel 2 ; Cruz, Maria Teresa 3   VIAFID ORCID Logo  ; Almeida, Isabel Filipa 2   VIAFID ORCID Logo 

 Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; [email protected] (D.S.); [email protected] (M.S.F.); [email protected] (J.M.S.-L.) 
 Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal; [email protected] (D.S.); [email protected] (M.S.F.); [email protected] (J.M.S.-L.); UCIBIO/REQUIMTE, MedTech, Laboratory of Pharmaceutical Technology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal 
 Faculty of Pharmacy, University of Coimbra, 3004-531 Coimbra, Portugal; [email protected]; Center for Neurosciences and Cell Biology, 3004-504 Coimbra, Portugal 
First page
31
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
20799284
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2544480633
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.